News20 hours ago
Psilera Unveils Novel, Non-Hallucinogenic Psilocybin Derivative PSIL-006 As Lead Clinical Candidate
PSIL-006 is the first drug candidate from Psilera’s extensive pipeline to progress into advanced safety studies prior to first-in-human clinical trials TAMPA, Fla., May 25, 2023...
